27 November 2017 in Nature Medicine
Degeneration of the retinal pigment epithelium is a hallmark of geographic atrophy, a type of age-related macular degeneration. Kerur et al. show that this degeneration results from a multistep pathway in which mitochondrial dysfunction in RPE cells, triggered by accumulation of Alu RNA, leads to activation of the noncanonical inflammasome via a cGAS–STING–IRF3 signaling axis. Geographic atrophy is a blinding form of age-related macular degeneration characterized by retinal pigmented epithelium (RPE) death; the RPE also exhibits DICER1 deficiency, resultant accumulation of endogenous Alu-retroelement RNA, and NLRP3-inflammasome activation. How the inflammasome is activated in this untreatable disease is largely unknown. Here we demonstrate that RPE degeneration in human-cell-culture and mouse models is driven by a noncanonical-inflammasome pathway that activates caspase-4 (caspase-11 in mice) and caspase-1, and requires cyclic GMP-AMP synthase (cGAS)-dependent interferon-β production and gasdermin D–dependent interleukin-18 secretion. Decreased DICER1 levels or Alu-RNA accumulation triggers cytosolic escape of mitochondrial DNA, which engages cGAS. Moreover, caspase-4, gasdermin D, interferon-β, and cGAS levels were elevated in the RPE in human eyes with geographic atrophy. Collectively, these data highlight an unexpected role of cGAS in responding to mobile-element transcripts, reveal cGAS-driven interferon signaling as a conduit for mitochondrial-damage-induced inflammasome activation, expand the immune-sensing repertoire of cGAS and caspase-4 to noninfectious human disease, and identify new potential targets for treatment of a major cause of blindness.
1 May 2009 in Ophthalmology
23 September 2020 in Nature Communications
Innate immune signaling through the NLRP3 inflammasome is activated by multiple diabetes-related stressors, but whether targeting the inflammasome is beneficial for diabetes is still unclear. Nucleoside reverse-transcriptase inhibitors (NRTI), drugs approved to treat HIV-1 and hepatitis B infections, also block inflammasome activation. Here, we show, by analyzing five health insurance databases, that the adjusted risk of incident diabetes is 33% lower in patients with NRTI exposure among 128,861 patients with HIV-1 or hepatitis B (adjusted hazard ratio for NRTI exposure, 0.673; 95% confidence interval, 0.638 to 0.710; P < 0.0001; 95% prediction interval, 0.618 to 0.734). Meanwhile, an NRTI, lamivudine, improves insulin sensitivity and reduces inflammasome activation in diabetic and insulin resistance-induced human cells, as well as in mice fed with high-fat chow; mechanistically, inflammasome-activating short interspersed nuclear element (SINE) transcripts are elevated, whereas SINE-catabolizing DICER1 is reduced, in diabetic cells and mice. These data suggest the possibility of repurposing an approved class of drugs for prevention of diabetes.
1 March 2011 in American Journal of Ophthalmology
20 October 2019 in Graefe's Archive for Clinical and Experimental Ophthalmology
1 November 2010 in Journal of Cataract & Refractive Surgery
To evaluate the repeatability and reproducibility of central corneal thickness (CCT), anterior chamber depth (ACD), and anterior chamber width (ACW) measurements using 3-dimensional (3-D) corneal and anterior segment optical coherence tomography (CAS-OCT) and 2-dimensional (2-D) anterior segment OCT (AS-OCT). Department of Ophthalmology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan. Nonrandomized clinical trial. The CCT, ACD, and ACW were measured in normal eyes using a prototype 3-D swept-source CAS-OCT device and a 2-D time-domain AS-OCT device (Visante). The coefficient of repeatability and reproducibility and the intraclass correlation coefficient (ICC) were calculated to evaluate the repeatability and reproducibility of the measurements. Eighty-five eyes (85 subjects) were evaluated. The mean CCT measurement was 557.5 μm ± 40.5 (SD) with CAS-OCT and 556.4 ± 39.4 μm with AS-OCT; the mean ACD measurement, 3.13 ± 0.40 mm and 3.16 ± 0.39 mm, respectively; and the mean ACW, 11.80 ± 0.47 mm and 11.79 ± 0.49 mm, respectively. There was no statistically significant difference in CCT or ACW measurements between the 2 devices (P>.05, Wilcoxon signed rank test). Although the ACD measurements were significantly different (P<.0001), the difference was small (0.03 mm). Significant linear correlations were found between the measurements of the 2 devices (P<.0001). The ICC was greater than 0.99 for CAS-OCT and greater than 0.96 for AS-OCT. Corneal and anterior segment OCT and AS-OCT provided comparable and well-correlated anterior ocular biometric measurements, with sufficient repeatability and reproducibility.